{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:08:12Z","timestamp":1788354492603,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13048-016-0220-4","type":"journal-article","created":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T13:56:22Z","timestamp":1456754182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers"],"prefix":"10.1186","volume":"9","author":[{"given":"Janusz","family":"Menkiszak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Chudecka-G\u0142az","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Gronwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Cymbaluk-P\u0142oska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Celewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"\u015awiniarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"W\u0119\u017cowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryszard","family":"Bedner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Zieli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Tarnowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Jakubowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"Kojs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,29]]},"reference":[{"key":"220_CR1","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1002\/cncr.29321","volume":"121","author":"JL Walker","year":"2015","unstructured":"Walker JL, Powell CB, Chen LM, Carter J, Bae Jump VL, Parker LP, et al. Society of Gynecologic Oncology Recommendations for the Prevention of Ovarian Cancer. Cancer. 2015;121:2108\u201320.","journal-title":"Cancer"},{"issue":"4","key":"220_CR2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/1049732310387798","volume":"21","author":"AF Howard","year":"2011","unstructured":"Howard AF, Balneaves LG, Bottorff JL, et al. Preserving the self: the process of decision making about hereditary breast cancer and ovarian cancer risk reduction. Qual Health Res. 2011;21(4):502\u201319.","journal-title":"Qual Health Res"},{"issue":"9","key":"220_CR3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/jmg.2008.058248","volume":"46","author":"DG Evans","year":"2009","unstructured":"Evans DG, Gaarenstroom KN, Stirling D, et al. Screening for familial ovarian cancer: poor survival of BRCA1\/2 related cancers. J Med Genet. 2009;46(9):593\u20137.","journal-title":"J Med Genet"},{"issue":"7","key":"220_CR4","doi-asserted-by":"crossref","first-page":"e1000114","DOI":"10.1371\/journal.pmed.1000114","volume":"6","author":"PO Brown","year":"2009","unstructured":"Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009;6(7):e1000114.","journal-title":"PLoS Med"},{"issue":"2","key":"220_CR5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2214\/AJR.09.3999","volume":"194","author":"C Gulden","year":"2010","unstructured":"Gulden C, Olopade OI. Risk assessment and genetic testing for ovarian cancer. AJR Am J Roentgenol. 2010;194(2):309\u201310.","journal-title":"AJR Am J Roentgenol"},{"key":"220_CR6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2011.10.032","volume":"24","author":"BA Goff","year":"2012","unstructured":"Goff BA, Lowe KA, Kane JC, Robertson MD, Gaul MA, Andersen MR. Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability. Gynecol Oncol. 2012;24:230\u20135.","journal-title":"Gynecol Oncol"},{"key":"220_CR7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ogc.2012.02.007","volume":"39","author":"BA Goff","year":"2012","unstructured":"Goff BA. Ovarian cancer: screening and early detection. Obstet Gynecol Clin North Am. 2012;39:183\u201394.","journal-title":"Obstet Gynecol Clin North Am"},{"key":"220_CR8","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1002\/cncr.26035","volume":"117","author":"BA Goff","year":"2011","unstructured":"Goff BA, Matthews B, Andrilla CH, et al. How are symptoms of ovarian cancer managed? A study of primary care physicians. Cancer. 2011;117:4414\u201323.","journal-title":"Cancer"},{"key":"220_CR9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/GRF.0b013e3182480523","volume":"55","author":"B Goff","year":"2012","unstructured":"Goff B. Symptoms associated with ovarian cancer. Clin Obstet Gynecol. 2012;55:36\u201342.","journal-title":"Clin Obstet Gynecol"},{"key":"220_CR10","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/cncr.23577","volume":"113","author":"MR Andersen","year":"2008","unstructured":"Andersen MR, Goff BA, Lowe KA, et al. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer. 2008;113:484\u20139.","journal-title":"Cancer"},{"key":"220_CR11","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","volume":"305","author":"SS Buys","year":"2011","unstructured":"Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305:2295\u2013303.","journal-title":"JAMA"},{"key":"220_CR12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1470-2045(11)70333-3","volume":"13","author":"L Gilbert","year":"2012","unstructured":"Gilbert L, Basso O, Sampalis J, et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol. 2012;13:285\u201391.","journal-title":"Lancet Oncol"},{"key":"220_CR13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ygyno.2009.10.087","volume":"116","author":"MR Andersen","year":"2010","unstructured":"Andersen MR, Goff BA, Lowe KA, et al. Use of a symptom index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010;116:378\u201383.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"220_CR14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.17772\/gp\/1735","volume":"85","author":"A Synowiec","year":"2014","unstructured":"Synowiec A, Wcis\u0142o G, Bodnar L, Gasowska-Bodnar A, Szczylik C. Screening for ovarian cancer in BRCA1\/BRCA2 mutations carriers. Ginekol Pol. 2014;85(5):377\u201381.","journal-title":"Ginekol Pol"},{"issue":"3","key":"220_CR15","first-page":"188","volume":"8","author":"R M\u0105dry","year":"2010","unstructured":"M\u0105dry R, Markowska A. Reduction of risk of developing BRCA-dependent cancer in BRCA1\/2 mutation carriers \u2013 novel approach to old paradigm. Curr Gynecol Oncol. 2010;8(3):188\u201399.","journal-title":"Curr Gynecol Oncol"},{"key":"220_CR16","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1055-9965.EPI-07-2703","volume":"17","author":"MH Greene","year":"2008","unstructured":"Greene MH, Piedmonte M, Alberts D, et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev. 2008;17:594\u2013604.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"220_CR17","doi-asserted-by":"crossref","first-page":"19.e1","DOI":"10.1016\/j.ajog.2010.05.038","volume":"204","author":"MH Greene","year":"2011","unstructured":"Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1\/2 mutation carriers? Am J Obstet Gynecol. 2011;204(1):19.e1\u20136.","journal-title":"Am J Obstet Gynecol"},{"key":"220_CR18","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1200\/JCO.2007.11.3449","volume":"25","author":"ND Kauff","year":"2007","unstructured":"Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol. 2007;25:2921\u20137.","journal-title":"J Clin Oncol"},{"issue":"5","key":"220_CR19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/CCO.0b013e3283499da9","volume":"23","author":"KC Long","year":"2011","unstructured":"Long KC, Kauff ND. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies. Curr Opin Oncol. 2011;23(5):526\u201330. Review.","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"220_CR20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/AOG.0b013e3181ec5fc1","volume":"116","author":"JS Berek","year":"2010","unstructured":"Berek JS, Chalas E, Edelson M, et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Society of Gynecologic Oncologists Clinical Practice Committee. Obstet Gynecol. 2010;116(3):733\u201343.","journal-title":"Obstet Gynecol"},{"issue":"15","key":"220_CR21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","volume":"32","author":"AP Finch","year":"2014","unstructured":"Finch AP, Lubinski J, M\u00f8ller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547\u201353.","journal-title":"J Clin Oncol"},{"key":"220_CR22","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Friebel TM, Singer CF, et al. Association of riskreducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967\u201375.","journal-title":"JAMA"},{"issue":"2","key":"220_CR23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"220_CR24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.2009.22.7991","volume":"28","author":"AW Kurian","year":"2010","unstructured":"Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1\/2 mutation carriers. J Clin Oncol. 2010;28(2):222\u201331.","journal-title":"J Clin Oncol"},{"issue":"7","key":"220_CR25","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/1055-9965.EPI-12-0201","volume":"21","author":"J Kotsopoulos","year":"2012","unstructured":"Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, et al. Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1089\u201396.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"220_CR26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ygyno.2004.09.039","volume":"96","author":"KA Metcalfe","year":"2005","unstructured":"Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96(1):222\u20136.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"220_CR27","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1086\/302922","volume":"66","author":"B G\u00f3rski","year":"2000","unstructured":"G\u00f3rski B, Byrski T, Huzarski T, et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet. 2000;66(6):1963\u20138.","journal-title":"Am J Hum Genet"},{"issue":"8302","key":"220_CR28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(82)92681-2","volume":"2","author":"JK Tobacman","year":"1982","unstructured":"Tobacman JK, Greene MH, Tucker MA, Costa J, Kase R, Fraumeni Jr JF. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet. 1982;2(8302):795\u20137.","journal-title":"Lancet"},{"issue":"3","key":"220_CR29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamasurg.2013.1006","volume":"148","author":"JV Sitzmann","year":"2013","unstructured":"Sitzmann JV, Wiebke EA. Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer. JAMA Surg. 2013;148(3):285\u201391.","journal-title":"JAMA Surg"},{"issue":"21","key":"220_CR30","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"TR Rebbeck","year":"2002","unstructured":"Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van\u2019t Veer L, Garber JE, et al. Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616\u201322.","journal-title":"N Engl J Med"},{"issue":"21","key":"220_CR31","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","volume":"346","author":"ND Kauff","year":"2002","unstructured":"Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609\u201315.","journal-title":"N Engl J Med"},{"issue":"8","key":"220_CR32","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","volume":"26","author":"ND Kauff","year":"2008","unstructured":"Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"220_CR33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","volume":"296","author":"A Finch","year":"2006","unstructured":"Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296(2):185\u201392.","journal-title":"JAMA"},{"issue":"3","key":"220_CR34","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00404-010-1476-3","volume":"283","author":"K Rhiem","year":"2011","unstructured":"Rhiem K, Foth D, Wappenschmidt B, Gevensleben H, B\u00fcttner R, Ulrich U, et al. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet. 2011;283(3):623\u20137.","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"220_CR35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10689-011-9435-0","volume":"10","author":"BE Kiely","year":"2011","unstructured":"Kiely BE, Friedlander ML, Milne RL, Stanhope L, Russell P, Jenkins MA, et al. kConFab Investigators, Hopper JL, Phillips KA. Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer. Fam Cancer. 2011;10(3):505\u201314.","journal-title":"Fam Cancer"},{"issue":"5","key":"220_CR36","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/IGC.0b013e31821bc7e3","volume":"21","author":"CB Powell","year":"2011","unstructured":"Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer. 2011;21(5):846\u201351.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"220_CR37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2005.01.039","volume":"97","author":"MJ Casey","year":"2005","unstructured":"Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol. 2005;97(2):457\u201367.","journal-title":"Gynecol Oncol"},{"issue":"22","key":"220_CR38","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1158\/1078-0432.CCR-08-0112","volume":"14","author":"L M\u00e6hle","year":"2008","unstructured":"M\u00e6hle L, Apold J, Paulsen T, Hagen B, L\u00f8vslett K, Fiane B, et al. High risk for ovarian cancer in a prospective series is restricted to BRCA1\/2 mutation carriers. Clin Cancer Res. 2008;14(22):7569\u201373.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"220_CR39","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/sj.bjc.6601692","volume":"90","author":"RI Olivier","year":"2004","unstructured":"Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, et al. Clinical outcome of prophylactic oophorectomy in BRCA1\/BRCA2 mutation carriers and events during follow-up. Br J Cancer. 2004;90(8):1492\u20137.","journal-title":"Br J Cancer"},{"issue":"1","key":"220_CR40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1525-1438.2006.00480.x","volume":"16","author":"KN Gaarenstroom","year":"2006","unstructured":"Gaarenstroom KN, van der Hiel B, Tollenaar RA, Vink GR, Jansen FW, van Asperen CJ, et al. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer. 2006;16(1):54\u20139.","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"220_CR41","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/cncr.22603","volume":"109","author":"F Laki","year":"2007","unstructured":"Laki F, Kirova YM, This P, Plancher C, Asselain B, Sastre X, et al. IC-BOCRSG IC-BOCRSG: Institut Curie - Breast Ovary Cancer Risk Study Group. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer. 2007;109(9):1784\u201390.","journal-title":"Cancer"},{"issue":"11","key":"220_CR42","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/ejhg.2009.60","volume":"17","author":"DG Evans","year":"2009","unstructured":"Evans DG, Clayton R, Donnai P, Shenton A, Lalloo F. Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. Eur J Hum Genet. 2009;17(11):1381\u20135.","journal-title":"Eur J Hum Genet"},{"issue":"11","key":"220_CR43","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1940-6207.CAPR-12-0190","volume":"5","author":"IE Fakkert","year":"2012","unstructured":"Fakkert IE, Mourits MJ, Jansen L, van der Kolk DM, Meijer K, Oosterwijk JC, et al. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers. Cancer Prev Res (Phila). 2012;5(11):1291\u20137.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"220_CR44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.canep.2010.06.007","volume":"35","author":"Y Ramon","year":"2011","unstructured":"Ramon Y, Cajal T, Torres A, Alonso C, Fisas D, Ojeda B, et al. Risk factors associated with the occurrence of breast cancer after bilateral salpingo-oophorectomy in high-risk women. Cancer Epidemiol. 2011;35(1):78\u201382.","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"220_CR45","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10549-009-0475-1","volume":"118","author":"P Shah","year":"2009","unstructured":"Shah P, Rosen M, Stopfer J, Siegfried J, Kaltman R, Mason B, et al. Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. Breast Cancer Res Treat. 2009;118(3):539\u201346.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"220_CR46","first-page":"3776","volume":"8","author":"JM Satagopan","year":"2002","unstructured":"Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res. 2002;8(12):3776\u201381.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-016-0220-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T07:12:46Z","timestamp":1498288366000},"score":1,"resource":{"primary":{"URL":"http:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-016-0220-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,29]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["220"],"URL":"https:\/\/doi.org\/10.1186\/s13048-016-0220-4","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,29]]},"article-number":"11"}}